company background image
OABI

OmniAb NasdaqGM:OABI Stock Report

Last Price

US$4.34

Market Cap

US$498.3m

7D

-0.5%

1Y

n/a

Updated

03 Feb, 2023

Data

Company Financials +

OABI Stock Overview

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States.

OABI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

New

Notes are coming soon

OmniAb, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OmniAb
Historical stock prices
Current Share PriceUS$4.34
52 Week HighUS$10.50
52 Week LowUS$1.91
Beta0
1 Month Change34.37%
3 Month Change100.93%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-51.45%

Recent News & Updates

Recent updates

Shareholder Returns

OABIUS Life SciencesUS Market
7D-0.5%2.7%2.9%
1Yn/a-10.4%-8.5%

Return vs Industry: Insufficient data to determine how OABI performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how OABI performed against the US Market.

Price Volatility

Is OABI's price volatile compared to industry and market?
OABI volatility
OABI Average Weekly Movement16.6%
Life Sciences Industry Average Movement11.7%
Market Average Movement6.8%
10% most volatile stocks in US Market17.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: OABI is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: Insufficient data to determine OABI's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201293Matt Foehrhttps://www.omniab.com

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company’s discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.

OmniAb, Inc. Fundamentals Summary

How do OmniAb's earnings and revenue compare to its market cap?
OABI fundamental statistics
Market CapUS$498.32m
Earnings (TTM)-US$32.23m
Revenue (TTM)US$39.01m

12.8x

P/S Ratio

-15.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OABI income statement (TTM)
RevenueUS$39.01m
Cost of RevenueUS$0
Gross ProfitUS$39.01m
Other ExpensesUS$71.24m
Earnings-US$32.23m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.28
Gross Margin100.00%
Net Profit Margin-82.61%
Debt/Equity Ratio0%

How did OABI perform over the long term?

See historical performance and comparison